The House of Lords Environment and Climate Change Committee today called for a ban on the general sale of flea and tick treatments for pets, following an inquiry that found widespread overuse of the products is polluting UK waterways without adequate scientific justification.
The cross-party committee's report, Paws for Concern: Pets, Parasites and Pollution, concluded that the "intensive and unnecessary overuse" of pet parasite medications is "not supported by robust scientific evidence" and is causing potential widespread damage to aquatic and terrestrial ecosystems. The inquiry, launched in May, gathered evidence from vets, pet charities, retailers, ecologists, and regulators.
The report singles out fipronil and imidacloprid, two neonicotinoid chemicals used in flea and tick shampoos, spot-on treatments, and tablets, many of which are sold over-the-counter or through monthly subscriptions. Both substances are already banned for agricultural use in the UK due to their toxicity to bees, fish, and other wildlife, yet remain widely available in pet products. UK rivers have been found to contain elevated concentrations of both chemicals.
The committee issued eight recommendations to the government and the Veterinary Medicines Directorate, including:
- A ban on general sale of flea and tick treatments in pet shops and online, restricting supply to vets, pharmacists, and other qualified professionals.
- A requirement for thorough assessment of individual pets' needs before treatment is prescribed, replacing routine monthly dosing.
- Development of a comprehensive evidence base tracking sales volumes, treatment rates, and actual parasite prevalence.
- Further research into the environmental and health impacts of both established parasiticides and newer alternatives such as isoxazolines, for which the committee said little safety data currently exists.
The report also flagged concerns that the pet pharmaceutical industry is embedded within the regulatory and advice-setting frameworks governing these products.
The government has said it is continuing to assess how the treatments are made available to ensure correct usage, but has not committed to implementing a sales ban.
Comments
Post a Comment